Aug 08, 2024 / 10:15AM GMT
James Quigley - Goldman Sachs - Analyst
Good morning, everybody. I'm James Quigley. European pharma manager here at Goldman Sachs, and it's a pleasure to welcome you here to the Novo second quarter management meeting.
So today we're joined by Lars Jørgensen, CEO; Karsten Knudsen, CFO; Camilla Sylvest, Head of Commercial; and also, Martin Lange, Head of Development. So with that all explained, I'll hand straight over to you guys to kick off.
Lars Fruergaard Joergensen - Novo Nordisk A/S-President - Chief Executive Officer
Good. Thank you. Thank you, James, and thank you, Goldman Sachs, for hosting us today. We're excited to be here. You have probably seen some of our slides. We'll go through them quickly just to set the stage and then get to the Q&A.
So the first slide is the forward-looking statements. You know we'll be talking about the future. It could turn out to be different than what we preach here, so be aware of that, and there are more notes in our website, et cetera.
So you
Q2 2024 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript
Aug 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers